Detection of clinically relevant early genomic lesions in B‐cell malignancies from circulating tumour DNA using a single hybridisation‐based next generation sequencing assay

Green, T.M., Young, K.H., Visco, C., Xu-Monette, Z.Y., Orazi, A., Go, R.S., Nielsen, O., Gadeberg, O.V., Mourits-Andersen, T., Frederiksen, M., Pedersen, L.M. & Møller, M.B. (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3460–3467. Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G.A., Zelenetz, A.D. & Jaffe, E.S. (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127, 2375–2390. Zhou, Z., Sehn, L.H., Rademaker, A.W., Gordon, L.I., Lacasce, A.S., Crosby-Thompson, A., Vanderplas, A., Zelenetz, A.D., Abel, G.A., Rodriguez, M.A., Nademanee, A., Kaminski, M.S., Czuczman, M.S., Millenson, M., Niland, J., Gascoyne, R.D., Connors, J.M., Friedberg, J.W. & Winter, J.N. (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 123, 837–842.